When Investors Want Out, Why Are Life Insurers Leaning In?

Private credit has a liquidity problem.

That does not mean the market is collapsing. It means investors are asking a harder question: how much extra return is worth giving up easy access to cash?

This week, Reuters reported that insurers and large institutions are preparing to put more money into private credit even as some wealthy investors grow more cautious about the market’s illiquidity. A Marsh survey cited in the report found that 57% of insurers plan to increase private-credit exposure over the next 12 to 24 months. Among life insurers, the figure was even higher.

That is the story.

The investors most worried about being locked in may be stepping back. Life insurers may be stepping forward.

At first, that sounds risky. But the picture is more complicated.

Life insurers are not ordinary investors. They collect premiums today and promise to pay benefits in the future. Some of those promises may stretch across decades. That long time horizon can make insurers natural buyers of assets that are harder to sell quickly.

But there is a limit to that argument.

A long-term liability does not make every illiquid asset safe. It only means the insurer may be better positioned to hold some assets if the risks are properly understood, valued, governed and capitalized.

That is where the market is heading next.

The private-credit question is no longer simply: who wants the yield?

It is: who can safely hold the risk?

Life insurers need investment income.

The basic life-insurance model depends on collecting premiums, investing assets and paying claims or benefits when due. Annuity writers face a similar challenge. They receive money today and promise future income or future account value guarantees.

That creates pressure to find assets that produce enough return to support promises made to policyholders.

Private credit can look attractive because it may offer higher yields than comparable public bonds. It can also offer customized terms, longer durations and exposure to assets that fit an insurer’s liability profile.

For a life insurer, that can be useful.

If the insurer expects to pay benefits over many years, it may not need every asset to be sold tomorrow. A long-term asset can be appropriate if it is matched against a long-term obligation.

This is the argument for insurer involvement in private credit: the liability is patient, so the asset can be patient too.

That argument has merit.

But it should not become an excuse for weak oversight.

Liquidity is the ability to turn an asset into cash quickly without taking a large loss.

Publicly traded bonds are generally more liquid than private loans. A private-credit investment may be harder to sell, harder to value and harder for outsiders to compare.

An insurer that holds private credit is making a trade-off.

It may receive additional yield. In return, it accepts less transparency, less market pricing and less flexibility if conditions change.

That trade-off can be reasonable when the asset is high quality and the insurer has stable liabilities.

It becomes more concerning when the insurer relies on private credit to stretch for yield, reduce apparent capital pressure or support aggressive annuity pricing.

The issue is not that private credit exists.

The issue is whether the additional return is enough compensation for the additional complexity.

Most policyholders do not read insurer investment schedules.

They buy life insurance because they want a death benefit to be paid. They buy annuities because they want income, protection or retirement certainty. They trust the insurer to manage the financial machinery behind the promise.

That machinery includes underwriting, reserves, capital, reinsurance, investment management and regulation.

Private credit sits inside that machinery.

If the assets perform as expected, policyholders may never notice them. If the assets are mispriced, too concentrated, too closely tied to affiliated parties or too hard to sell during stress, the issue can become more serious.

A policyholder does not need to understand every loan in an insurer’s portfolio.

But the policyholder does need the insurer, regulator and rating agencies to understand them.

That is the trust chain.

Regulators are not trying to ban insurers from investing.

They are trying to make sure insurance promises remain credible when business models change.

Europe’s insurance regulator has warned that private-equity buyers of insurers must show long-term commitment to policyholders, not only a short-term investment plan. Regulators are also paying attention to affiliated investments, private credit exposure and complex reinsurance arrangements that may move risk within a group or into less visible structures.

That concern applies beyond Europe.

The global insurance market is being reshaped by asset managers, private capital, offshore reinsurance and increasingly complex investment structures.

The more complicated the structure becomes, the more important the basic question becomes: where is the risk, and who is responsible for it?

If the answer requires a diagram, the regulation needs to be strong enough to follow the diagram.

It would be too easy to say private credit is bad.

That is not the right conclusion.

Private credit can finance companies, infrastructure, asset-backed lending and other investments that may not fit neatly into public markets. It can provide borrowers with flexible capital and investors with attractive income.

Life insurers can be legitimate participants in that market.

In fact, insurers may sometimes be better private-credit investors than short-term investors because they are not forced to sell at the first sign of stress.

But that advantage depends on discipline.

A life insurer should be able to show what it owns, how the asset is valued, how the asset behaves under stress, whether the asset is linked to affiliated parties, whether the yield reflects real risk, whether capital charges are appropriate, whether liquidity needs are properly modeled, and how the investment supports policyholder obligations.

The weakest answer is: the asset pays more, so it must be better.

This story matters especially because annuity sales remain strong.

Annuity buyers often want security, income or protection from retirement uncertainty. Insurers compete by offering rates, guarantees and product features that depend partly on investment performance.

If private credit helps insurers support better guarantees responsibly, it may benefit the market.

But if higher yields are used to make products appear more attractive while the risks are less visible, the market has a problem.

The consumer sees the rate.

The insurer sees the asset.

The regulator must see the risk.

That is why private-credit growth is not just an investment story. It is a product story, a solvency story and a policyholder-protection story.

Most advisors are not expected to audit insurer portfolios.

But advisors should understand that a guarantee is not magic. It depends on the issuing insurer’s financial strength and claims-paying ability.

When recommending annuities or permanent life insurance products with long-term guarantees, advisors should avoid treating all insurers as interchangeable.

The questions may be simple: who is issuing the guarantee, how financially strong is the insurer, what are the liquidity restrictions, what happens if the client needs access to funds, and how does this product solve the client’s problem?

Those questions do not require a private-credit lecture. They require professional discipline.

A good advisor explains the promise without overselling certainty.

For policyholders, this story is a reminder that the strength of a life insurance or annuity guarantee depends on more than the product brochure.

For advisors, it reinforces the importance of insurer selection, suitability and plain-language explanation.

For insurers, it highlights the need for strong governance, capital discipline and transparent investment risk management.

For regulators, it shows why oversight must keep pace with private markets, affiliated transactions and reinsurance structures.

Private credit can be useful patient capital.

But the patient money belongs, ultimately, to policyholders.

That is why the risk must be visible.